Buy & Sell Alnylam Pharmaceuticals, Inc. (ALNY) – Alnylam Pharmaceuticals, Inc. Price Today
Aura AI Summary
Key Stats
- $40.73BMarket Cap
- HealthSector
- -16.08%3M Drawdown
- $38.99BEnterprise Value
- -Dividend Yield
- 41 daysTypical Hold Time
Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $40.73B, with an enterprise value of $38.99B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $284.84 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -16.08%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 41 days, indicating typical investor behavior on the platform.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Most Recent News
Allied Gold receives key regulatory approvals, extends deal deadline with Zijin Gold to July 29, 2026.
Allied Gold Corporation announced that Zijin Gold has received approval under the Investment Canada Act for its proposed acquisition of Allied Gold. This approval completes the Canadian regulatory process for the transaction. The deal has also cleare...

Universal Music Group rejects Pershing Square's undervalued buyout proposal, confident in growth strategy.
Universal Music Group's Board of Directors unanimously rejected an unsolicited buyout proposal from Pershing Square Capital Management, stating it undervalues the company and won't create superior value. The Board, supported by shareholders, highligh...

Broadcom gains billionaire investor as AI chip demand boosts stock and revenue forecasts.
Hedge fund billionaire Daniel Loeb increased his stake in Broadcom by buying 50,000 shares while reducing holdings in NVIDIA and Taiwan Semiconductor. Broadcom reported strong Q1 revenue of $19.31 billion, beating estimates, and expects Q2 revenue ar...
